Physician profile
Sara E Damron
NPI 1104340645
$1,546.42
in general payments reported to CMS, 2019-2025
14 companies · $186 in 2025
The $186 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.52 · 2022: $750 · 2023: $125 · 2024: $393 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $270.00 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $166.38 | 2022 | |
| Novo Nordisk INC | $152.38 | 2022 | |
| Scynexis, INC. | $140.16 | 2022 | |
| Bioventus LLC | $136.39 | 2022 | |
| Amgen INC. | $111.03 | 2023 | Otezla |
| Astrazeneca Pharmaceuticals LP | $100.62 | 2021-2022 | |
| Mdd US Operations, LLC | $100.47 | 2024 | Apokyn |
| Lundbeck LLC | $98.24 | 2025 | Vyepti |
| Neurocrine Biosciences, INC. | $96.06 | 2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.46 | 2025 | Caplyta |
| Grt US Holding, INC. | $57.73 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.84 | 2021 | |
| Glaxosmithkline, LLC. | $13.66 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Damron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.